Navamedic Financial Report for Q1 2013

Navamedic ASA (OSE: NAVA), the Norwegian pharmaceutical products company, today announced its first quarter 2013 results. Following a 65 per cent sales growth, Navamedic posted sales income of NOK 34.0 million in the quarter. EBITDA for the first quarter was NOK 3.5 million, compared to 0.1 million last year. The first quarter EBITDA included a one-off royalty payment of NOK 2.6 million related to the sale of Navamedic's Glucomed business four years ago. The Company's net result for the quarter ended at NOK 1.4 million, compared to NOK -1.0 million in the first quarter 2012.

Contact Navamedic:

CEO Olof Milveden mob: +46 73 34 63 73 6
CFO Bjørn Lindholt mob: +47  93 00 66 01